CODX

SALT LAKE CITY, Nov. 5, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it will release its third quarter 2026 financial results on Tuesday, November 10, 2026, after the market close, rather than the previously announced date of Thursday, November 12, 2026. The Company will also host a conference call and webcast on the same day at 4:30 p.m.

Events in Bali and Rio de Janeiro Bring Together Global Health Leaders to Address Tuberculosis Diagnosis, Treatment and Prevention SALT LAKE CITY, Nov. 5, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the Company will participate in three global tuberculosis ("TB") events in November 2026: 40th Stop TB Partnership Board Meeting and Related Events – November 3-6, 2026, Bali, Indonesia: The Company will attend the Stop TB Partnership's board meeting and related events, co-hosted with the Government of the Republic of Indonesia and the Tahir Foundation. 4th Annual New Tools Summit – November 16, 2026, Rio de Janeiro, Brazil: Co-Dx will attend the summit, hosted by the working groups of the Stop TB Partnership.

SALT LAKE CITY, Oct. 29, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced it will release its third quarter 2026 financial results on Thursday, November 12, 2026, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m.

Follow-Up Biopsies Identified High-Grade Lesions or Cervical Cancer in 12 of 20 HPV-Positive Women, Including a Cohort with Predominantly Negative Cytology Results CoSara to Exhibit at MICROCON 2026, the Annual Congress of the Indian Association of Medical Microbiologists Co-Dx to Host HPV Screening Webinar on November 17 to Support Awareness Across South Asian Markets SALT LAKE CITY, Oct. 29, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the publication of a peer-reviewed study using the SARAGENE® Human Papillomavirus High Risk (HPV-HR) Test manufactured by CoSara Diagnostics Pvt. Ltd. ("CoSara"), the Company's joint venture in India.

CDSCO Clearance and Commercial Launch in India Anticipated Before Year-End 2026 Study Demonstrated 97.3% Sensitivity and 96.0% Specificity Consistent Performance Across Three Test Batches Integrated Mobile and Cloud Infrastructure Already Deployed in India to Support AnticipatedCommercial Launch SALT LAKE CITY, Oct. 27, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that CoSara Diagnostics Pvt. Ltd. ("CoSara"), the Company's joint venture in India, has completed its clinical performance study of the CoSara PCR Mycobacterium tuberculosis ("MTB" or "TB") test on the CoSara PCR Pro® instrument* and has submitted the test to India's Central Drugs Standard Control Organization ("CDSCO") for regulatory clearance.

Participation in NUWATIN 2026 to Support Advancement of Strategic Manufacturing, Technology Transfer, and Industrial Localization Initiatives Under Saudi Vision 2030 Invitation Follows Execution of Manufacturing Facility Lease in Sudair Industrial City SALT LAKE CITY, Oct. 20, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that CoMira Diagnostics ("CoMira"), the Company's joint venture with Arabian Eagle Manufacturing in the Kingdom of Saudi Arabia ("KSA"), has been invited by the Kingdom's Ministry of Industry and Mineral Resources to participate in the second edition of the NUWATIN 2026 Forum, scheduled for November 2026. The forum will be held under the patronage and in the presence of His Royal Highness Prince Abdulaziz bin Salman Al Saud, Minister of Industry and Mineral Resources.

Existing Sputum Sample-Preparation Technology Provides Potential Foundation for Plague Diagnostics Draws on Rapid-Response Experience with COVID-19, Mpox and Ebola Supported by Expanded Manufacturing Infrastructure SALT LAKE CITY, Oct. 15, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today highlighted capabilities of its Co-Dx PCR Pro®* point-of-care platform that could be applied to plague diagnostics, should a public health need arise. The Company is monitoring developments following the October 2 death of a laboratory worker at a plague research institute in Irkutsk, Russia.

Ute Indian Tribe Mosquito Abatement Department to bring PCR-based mosquito surveillance testing in house SALT LAKE CITY, Oct. 8, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has received an order from the Ute Indian Tribe Mosquito Abatement Department for a full Vector Smart® mosquito surveillance laboratory installation. The order represents the Company's first complete Vector Smart laboratory installation for a Native American tribe and will enable the Tribe to perform PCR testing of mosquito pools in house.

New Executive Order prioritizes improved detection and calls for federal R&D programs for rapid diagnostics for mosquito- and tick-borne diseases Company to participate in October 9 Utah Global Health Leadership roundtable and four regional mosquito control conferences this fall SALT LAKE CITY, Oct. 7, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today highlighted the growing commercial momentum of its Vector Smart® mosquito surveillance business following the September 29, 2026 signing of Executive Order 14433, "Eliminating Disease-Carrying Pests and Restoring Enjoyment of the Great Outdoors" (the "Executive Order"). The Executive Order establishes a federal initiative focused on suppressing tick and mosquito populations and addressing vector-borne disease through improved detection, screening, prevention and health care interventions.

Ebola Assay in Development for Decentralized Testing on the Co-Dx PCR Platform SALT LAKE CITY, Oct. 6, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced its upcoming participation at WHX Labs Johannesburg, taking place October 6-8, 2026, at the Gallagher Convention Centre in Johannesburg, South Africa. Attendees are invited to join Co-Dx at Booth # H3.L38, where the Company will showcase the Co-Dx PCR platform and the Co-Dx™ PCR MTB test*.